TOBRAMYCIN AND DEXAMETHASONE
Clinical safety rating: avoid
Other nephrotoxic or ototoxic drugs increase risk of toxicity Monitor peak and trough levels to minimize risk of nephrotoxicity and ototoxicity.
Tobramycin: aminoglycoside antibiotic that binds to bacterial 30S ribosomal subunit, inhibiting protein synthesis and causing misreading of mRNA. Dexamethasone: corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and stabilizing lysosomal membranes.
| Metabolism | Tobramycin: minimal metabolism, primarily excreted unchanged by glomerular filtration. Dexamethasone: metabolized primarily in the liver by CYP3A4 to inactive metabolites. |
| Excretion | Tobramycin is eliminated primarily by the kidneys via glomerular filtration, with 80-90% of an absorbed dose excreted unchanged in urine over 24 hours; minor biliary/fecal excretion (<1%). Dexamethasone is metabolized in the liver and excreted in urine (65%) and feces (35%) as metabolites. |
| Half-life | Tobramycin: 2-3 hours in patients with normal renal function; prolonged (24-60 hours) in renal impairment. Dexamethasone: 3-5 hours in adults; prolonged in hepatic impairment. |
| Protein binding | Tobramycin: <10% bound to plasma proteins. Dexamethasone: 70-80% bound to albumin. |
| Volume of Distribution | Tobramycin: 0.2-0.3 L/kg (confined to extracellular fluid); increased Vd in edema, ascites, or burns. Dexamethasone: 0.6-1.0 L/kg (distributes widely). |
| Bioavailability | Ophthalmic suspension: Systemic bioavailability is negligible (topical route, minimal absorption through cornea/conjunctiva). Not administered orally or parenterally for this indication. |
| Onset of Action | Ophthalmic suspension: Onset of anti-inflammatory effect within 24 hours; antibacterial effect within 1-2 hours. Topical (eye): Clinical improvement in signs/symptoms typically within 2-3 days. |
| Duration of Action | Ophthalmic: Dosing every 4-6 hours yields sustained effect; use for 7-10 days typically. Duration varies with infection/inflammation severity. |
| Molecular Weight | 467.51 Da (tobramycin base); dexamethasone: 392.46 Da; combined: composite not applicable. |
1-2 drops of suspension into the conjunctival sac every 4-6 hours; in severe cases, every 2 hours initially, then taper.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No systemic absorption at ophthalmic doses; no adjustment required. |
| Liver impairment | No systemic absorption at ophthalmic doses; no adjustment required. |
| Pediatric use | 1 drop into affected eye(s) every 4-6 hours; not recommended for children <2 years due to potential for adrenal suppression. |
| Geriatric use | No specific dose adjustment; use lowest effective dose for shortest duration due to increased risk of intraocular pressure elevation and cataract formation. |
| 1st trimester | Avoid; aminoglycosides can cause fetal ototoxicity; category D for tobramycin; corticosteroids may increase risk of oral clefts. |
| 2nd trimester | Use only if benefit outweighs risk; potential for fetal ototoxicity and nephrotoxicity; prolonged use of corticosteroids may affect fetal growth. |
| 3rd trimester | Avoid near term; risk of neonatal ototoxicity and nephrotoxicity; corticosteroids may suppress fetal adrenal function. |
Clinical note
Other nephrotoxic or ototoxic drugs increase risk of toxicity Monitor peak and trough levels to minimize risk of nephrotoxicity and ototoxicity.
| FDA category | Positive |
| Placental transfer | Tobramycin crosses the placenta to a limited extent; dexamethasone readily crosses the placenta. |
| Breastfeeding |
■ FDA Black Box Warning
No FDA boxed warning for ophthalmic use. Systemic aminoglycosides have boxed warnings for nephrotoxicity, ototoxicity, and neuromuscular blockade but these are not applicable to ophthalmic formulations.
| Common Effects | Nephrotoxicity |
| Serious Effects |
Hypersensitivity to tobramycin, dexamethasone, or any componentActive ocular infections (viral, fungal, mycobacterial) without appropriate therapyOcular herpes simplex
| Precautions | Prolonged use may result in ocular hypertension/glaucoma, cataract formation, secondary infection (including fungal infections), and delayed wound healing. In patients with known or suspected glaucoma, intraocular pressure should be monitored. Cross-sensitivity to other aminoglycosides may occur. |
| Food/Dietary | No significant food interactions. Avoid alcohol because it can worsen eye irritation and cause flushing. No other dietary restrictions. |
Loading safety data…
| Tobramycin is excreted in breast milk in low concentrations; dexamethasone is poorly excreted; use with caution due to potential for ototoxicity and disruption of infant's gut flora. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | TOBRAMYCIN AND DEXAMETHASONE: Tobramycin is an aminoglycoside; associated with potential ototoxicity and nephrotoxicity in the fetus, especially in the second and third trimesters. Dexamethasone is a corticosteroid; chronic high doses increase risk of oral clefts (first trimester), intrauterine growth restriction, and adrenal suppression in the newborn. Overall, limited human data; risk cannot be excluded. Use only if clearly needed. |
| Fetal Monitoring | Monitor maternal renal function, hearing, and vestibular toxicity during prolonged systemic use. For ophthalmic use, routine monitoring is not required. In pregnancy, assess fetal growth if high doses or prolonged use of dexamethasone. |
| Fertility Effects | No specific studies on fertility effects of this combination. Tobramycin may impair fertility in males at high systemic doses (spermatotoxic). Dexamethasone may disrupt menstrual cycles and reduce fertility at high doses. Clinically, ophthalmic use is unlikely to impact fertility. |
| Clinical Pearls | The combination product Tobramycin/Dexamethasone ophthalmic suspension or ointment is indicated for steroid-responsive ocular inflammatory conditions with or without superficial bacterial infection. It should not be used for uncomplicated conjunctivitis or viral/fungal infections because steroids exacerbate these conditions. Prolonged use (over 2 weeks) increases risk of elevated intraocular pressure, cataracts, and secondary infections. Monitor IOP if used beyond 10 days, especially in patients with glaucoma. Shake suspension well before use. Do not touch dropper tip to any surface. In patients with corneal abrasion, use with caution as steroids can delay healing. For bacterial keratitis, tobramycin component is effective against many gram-negative organisms, but not reliable for Pseudomonas aeruginosa with monotherapy; however, combination with dexamethasone may be adequate for initial treatment of bacterial keratitis when used with caution. |
| Patient Advice | Use exactly as prescribed; do not use for longer than recommended without consulting your doctor. · Shake the bottle vigorously before each use to ensure the medicine is well mixed. · Do not touch the dropper tip to your eye or any surface to prevent contamination. · Remove contact lenses before applying and wait at least 15 minutes before reinserting (if not contraindicated). · Temporary stinging or blurred vision may occur; do not drive until vision clears. · Report any eye pain, vision changes, or worsening redness immediately. · Do not share this medicine with others, even if they have similar symptoms. · Store at room temperature, away from heat and light, and keep bottle tightly closed. |